ERBB2 and renal pelvis/ureter urothelial carcinoma: Irrespective of their ERBB2 status, patients with UTUC treated with platin showed a significantly lower PFS than patients with UTUC who had not received any platin-based therapy (p < 0.001, 95% CI = 3.865–16.851, HR = 8.192; Table 5, univariable Cox regression, Figure 2D), a result which persisted in the multiple regression approach (Table 5, right panel).